Summary

The global anti-rheumatics market is set for significant growth, with market size expected to increase from US$57.9 billion in 2023 to US$76.0 billion by 2030, expanding at a CAGR of 4%. Key factors driving this growth include the rising prevalence of rheumatic diseases, advancements in biologic therapies, and an increasing focus on early diagnosis and intervention. This press release delves into the key growth determinants, major barriers, emerging trends, regional frontrunners, and Competitve Analysis shaping the future of the anti-rheumatics market.

Key Growth Determinants

Advancements in Biologic Therapies

Ongoing developments in biologic medicines significantly drive the anti-rheumatics market. Biologics offer tailored therapy techniques for autoimmune disorders such as psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. Examples include B-cell-focused treatments, TNF-alpha inhibitors, and interleukin inhibitors. Compared to traditional disease-modifying drugs, these therapies show higher efficacy in lowering inflammation, managing disease activity, and delaying the course of the illness. The creation of biosimilars has also improved treatment affordability and accessibility, further propelling market expansion.

Increasing Prevalence of Rheumatic Diseases

One major factor propelling the anti-rheumatics industry is the increasing global prevalence of rheumatic disorders. Sedentary lifestyles, ageing population demographics, and environmental variables contribute to the rising prevalence of illnesses like lupus, osteoarthritis, and rheumatoid arthritis. There is an increasing need for efficient treatment alternatives as chronic illnesses have a major negative influence on patients' quality of life and come with high healthcare expenses. This demographic trend fuels the need for anti-rheumatic drugs, contributing to increased disease awareness and diagnostic rates, propelling market expansion.

Focus on Early Diagnosis and Intervention

The growing emphasis on early diagnosis and intervention represents a key driver for the anti-rheumatics market. Early detection and treatment initiation are crucial for preventing irreversible joint damage, deformities, and disability in rheumatic diseases. Consequently, healthcare providers and policymakers are increasingly promoting strategies for early screening, diagnosis, and referral of patients with symptoms suggestive of rheumatic conditions. This proactive approach not only improves patient outcomes but also drives the demand for anti-rheumatic drugs, including DMARDs, NSAIDs, and corticosteroids.

Major Growth Barriers

High Expense of Biological Treatments

The high cost of biologic therapy severely constrains the market for anti-rheumatoid arthritis drugs. The high cost of developing, producing, and delivering these drugs places a significant financial strain on payers, healthcare systems, and patients. Biologics are frequently out of reach due to cost concerns, which impedes market expansion, especially in healthcare settings with limited resources.

Potential Safety Concerns and Side Effects

Side effects and safety issues associated with anti-rheumatic drugs are a hindrance to market expansion. Although biological medicines provide focused treatment modalities, there is a chance of severe infections, immune suppression, and unfavourable responses. Furthermore, prolonged use of corticosteroids and NSAIDs is linked to renal, cardiovascular, and gastrointestinal problems, which restricts their general usage and acceptance. Because of these safety concerns, market dynamics are impacted by the need for rigorous risk-benefit analysis and monitoring.

Key Trends and Opportunities to Look at

Rise in Demand for Biosimilars

In the anti-rheumatics sector, biosimilars are becoming more and more popular since they provide affordable substitutes for branded biologic treatments. Driven by the goal to lower healthcare costs and increase treatment accessibility, this movement is widespread. Important companies like Novartis and Pfizer are putting money into the development of biosimilars, increasing market share and rivalry. Brands will likely use biosimilars to increase their competitiveness in the market, provide more accessible treatment alternatives, and take advantage of the rising demand around the world.

Personalised Medicines

In the anti-rheumatics industry, there is a shift towards personalised medicine with a growing emphasis on patient-specific treatment regimens, biomarker testing, and genetic profiling. Growing awareness of disease heterogeneity and improvements in precision medicine technologies are the main causes behind the increasing popularity of this approach in North America and Europe. Offering individualised treatment plans, businesses like Roche and AbbVie are driving advancements in companion diagnostics and targeted therapies. Companies are expected to use personalised medicine to improve patient outcomes, increase treatment efficacy, and set themselves apart from competitors.

Digital Health Solutions

The anti-rheumatics market is changing thanks to digital health tools that allow for remote monitoring, patient involvement, and therapy optimisation. Global telemedicine and wearable device use are the main drivers of this trend. To improve disease management, businesses like Johnson & Johnson and Eli Lilly are investing in digital health platforms that integrate data analytics and artificial intelligence. Brands will likely utilise digital health solutions to enhance patient adherence, gather real-time data, and provide value-added services that meet the changing demands and preferences of patients.

Regional Frontrunners

North America to Occupy the Largest Market Share

In the worldwide anti-rheumatics market, North America is positioned to hold the largest share. The high frequency of rheumatic disorders, the sophisticated healthcare system, and the region's intensive R&D efforts are all contributing causes to this supremacy. Strong regulatory frameworks and advantageous reimbursement policies also contribute to the growth of the market in North America. The region's leadership in the anti-rheumatics industry is being cemented by the research and product development driven by major pharmaceutical companies based in the US and Canada.

Asia Pacific to be Highly Assertive in Compound Growth During Forecast

The anti-rheumatics market is predicted to develop at the quickest rate in Asia Pacific. The region's growing patient base, rising healthcare costs, and quick economic growth all support market expansion. The demand for anti-rheumatic medications is driven in Asia Pacific by increased knowledge of rheumatic disorders, better access to healthcare facilities, and the adoption of cutting-edge treatment methods. Additionally, partnerships between pharmaceutical firms and government programs to improve the region's healthcare system and encourage illness management help to drive market expansion. Because of this, market participants in Asia Pacific have a lot of chances to build their businesses and take advantage of the rising demand for anti-rheumatic drugs.

Competitve Analysis Analysis

The market in terms of competition is propelled by personalised medicine, digital health solutions, and a growing emphasis on biosimilars. Biosimilars, being more affordable than branded biologic medicines, have increased manufacturer competition. Personalised medicine techniques like genetic profiling and biomarker testing enable businesses to create customised treatments and set themselves apart from competitors. The incorporation of digital health solutions, such as wearable technology and telemedicine, enhances patient outcomes and involvement during treatment. Companies in the anti-rheumatic drugs industry that innovate and adjust to these changes will have a competitive advantage.

Leading Companies in the Global Anti-Rheumatics Market

• Pfizer Inc.

• Novartis AG

• HOFFMANN LA ROCHE LTD

• Johnson & Johnson

• Eli Lilly And Company

• Abbvie Inc.

• Amgen Inc.

• BRISTOL - MYERS SQUIBB Company

• Merck & Co. Inc.

• UCB S.A.

• Celgene Corporations

• MedImmune, LLC

• Takeda Pharmaceutical Company Ltd.

• Biogen Inc.

• Celltrion Inc.

• Galapagos NV

• Mitsubishi Tanabe Pharma

• Boehringer Ingelheim Pharmaceuticals

• Gilead Sciences Inc.



Global Anti-rheumatics Market is Segmented as Below:

By Drug Class:

• Disease Modifying Anti-rheumatics Drugs (DMARDs)

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

• Corticosteroids

• Uric Acid Drugs

• Others

By Type:

• Prescription-Based Drugs

• Over-the-Counter Drugs

By Geographic Coverage:

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Italy

o Turkey

o Russia

o Rest of Europe

• Asia Pacific

o China

o Japan

o South Korea

o India

o Southeast Asia

o Rest of Asia Pacific

• Latin America

o Brazil

o Mexico

o Argentina

o Rest of Latin America

• Middle East & Africa

o GCC

o South Africa

o Egypt

o Nigeria

o Rest of the Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Anti-rheumatics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. Covid-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Anti-rheumatics Market Outlook, 2018 - 2030
3.1. Global Anti-rheumatics Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Disease Modifying Anti-rheumatics Drugs (DMARD's)
3.1.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAID's)
3.1.1.3. Corticosteroids
3.1.1.4. Uric Acid Drugs
3.1.1.5. Others
3.2. Global Anti-rheumatics Market Outlook, by Type, Value (US$ Mn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Prescription-Based Drugs
3.2.1.2. Over-the-Counter Drugs
3.3. Global Anti-rheumatics Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Anti-rheumatics Market Outlook, 2018 - 2030
4.1. North America Anti-rheumatics Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Disease Modifying Anti-rheumatics Drugs (DMARD's)
4.1.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAID's)
4.1.1.3. Corticosteroids
4.1.1.4. Uric Acid Drugs
4.1.1.5. Others
4.2. North America Anti-rheumatics Market Outlook, by Type, Value (US$ Mn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Prescription-Based Drugs
4.2.1.2. Over-the-Counter Drugs
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Anti-rheumatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. U.S. Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
4.3.1.2. U.S. Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
4.3.1.3. Canada Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
4.3.1.4. Canada Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Anti-rheumatics Market Outlook, 2018 - 2030
5.1. Europe Anti-rheumatics Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Disease Modifying Anti-rheumatics Drugs (DMARD's)
5.1.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAID's)
5.1.1.3. Corticosteroids
5.1.1.4. Uric Acid Drugs
5.1.1.5. Others
5.2. Europe Anti-rheumatics Market Outlook, by Type, Value (US$ Mn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Prescription-Based Drugs
5.2.1.2. Over-the-Counter Drugs
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Anti-rheumatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Germany Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
5.3.1.2. Germany Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
5.3.1.3. U.K. Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
5.3.1.4. U.K. Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
5.3.1.5. France Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
5.3.1.6. France Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
5.3.1.7. Italy Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
5.3.1.8. Italy Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
5.3.1.9. Turkey Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
5.3.1.10. Turkey Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
5.3.1.11. Russia Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
5.3.1.12. Russia Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
5.3.1.13. Rest of Europe Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
5.3.1.14. Rest of Europe Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Anti-rheumatics Market Outlook, 2018 - 2030
6.1. Asia Pacific Anti-rheumatics Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Disease Modifying Anti-rheumatics Drugs (DMARD's)
6.1.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAID's)
6.1.1.3. Corticosteroids
6.1.1.4. Uric Acid Drugs
6.1.1.5. Others
6.2. Asia Pacific Anti-rheumatics Market Outlook, by Type, Value (US$ Mn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Prescription-Based Drugs
6.2.1.2. Over-the-Counter Drugs
6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Anti-rheumatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. China Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
6.3.1.2. China Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
6.3.1.3. Japan Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
6.3.1.4. Japan Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
6.3.1.5. South Korea Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
6.3.1.6. South Korea Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
6.3.1.7. India Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
6.3.1.8. India Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
6.3.1.9. Southeast Asia Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
6.3.1.10. Southeast Asia Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
6.3.1.11. Rest of Asia Pacific Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
6.3.1.12. Rest of Asia Pacific Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Anti-rheumatics Market Outlook, 2018 - 2030
7.1. Latin America Anti-rheumatics Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Disease Modifying Anti-rheumatics Drugs (DMARD's)
7.1.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAID's)
7.1.1.3. Corticosteroids
7.1.1.4. Uric Acid Drugs
7.1.1.5. Others
7.2. Latin America Anti-rheumatics Market Outlook, by Type, Value (US$ Mn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Prescription-Based Drugs
7.2.1.2. Over-the-Counter Drugs
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Anti-rheumatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Brazil Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
7.3.1.2. Brazil Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
7.3.1.3. Mexico Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
7.3.1.4. Mexico Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
7.3.1.5. Argentina Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
7.3.1.6. Argentina Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
7.3.1.7. Rest of Latin America Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
7.3.1.8. Rest of Latin America Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Anti-rheumatics Market Outlook, 2018 - 2030
8.1. Middle East & Africa Anti-rheumatics Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Disease Modifying Anti-rheumatics Drugs (DMARD's)
8.1.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAID's)
8.1.1.3. Corticosteroids
8.1.1.4. Uric Acid Drugs
8.1.1.5. Others
8.2. Middle East & Africa Anti-rheumatics Market Outlook, by Type, Value (US$ Mn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Prescription-Based Drugs
8.2.1.2. Over-the-Counter Drugs
8.2.2. Middle East & Africa Anti-rheumatics Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
8.2.3. Key Highlights
8.2.3.1. GCC Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
8.2.3.2. GCC Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
8.2.3.3. South Africa Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
8.2.3.4. South Africa Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
8.2.3.5. Egypt Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
8.2.3.6. Egypt Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
8.2.3.7. Nigeria Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
8.2.3.8. Nigeria Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
8.2.3.9. Rest of Middle East & Africa Anti-rheumatics Market by Drug Class, Value (US$ Mn), 2018 - 2030
8.2.3.10. Rest of Middle East & Africa Anti-rheumatics Market Type, Value (US$ Mn), 2018 - 2030
8.2.4. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. End User vs Type Heatmap
9.2. Manufacturer vs Type Heatmap
9.3. Company Market Share Analysis, 2022
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Pfizer Inc.
9.5.1.1. Company Overview
9.5.1.2. Drug Class Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Novartis AG
9.5.2.1. Company Overview
9.5.2.2. Drug Class Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. HOFFMANN LA ROCHE LTD
9.5.3.1. Company Overview
9.5.3.2. Drug Class Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Johnson & Johnson
9.5.4.1. Company Overview
9.5.4.2. Drug Class Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Eli Lilly And Company
9.5.5.1. Company Overview
9.5.5.2. Drug Class Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Abbvie Inc.
9.5.6.1. Company Overview
9.5.6.2. Drug Class Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Amgen Inc.
9.5.7.1. Company Overview
9.5.7.2. Drug Class Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. BRISTOL - MYERS SQUIBB Company
9.5.8.1. Company Overview
9.5.8.2. Drug Class Portfolio
9.5.8.3. Business Strategies and Development
9.5.9. Merck & Co. Inc.
9.5.9.1. Company Overview
9.5.9.2. Drug Class Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. UCB S.A.
9.5.10.1. Company Overview
9.5.10.2. Drug Class Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Celegene Corporations
9.5.11.1. Company Overview
9.5.11.2. Drug Class Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. MedImmune, LLC
9.5.12.1. Company Overview
9.5.12.2. Drug Class Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Takeda Pharmaceutical Company Ltd.
9.5.13.1. Company Overview
9.5.13.2. Drug Class Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. Biogen Inc.
9.5.14.1. Company Overview
9.5.14.2. Drug Class Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
9.5.15. Celltrion Inc.
9.5.15.1. Company Overview
9.5.15.2. Drug Class Portfolio
9.5.15.3. Financial Overview
9.5.15.4. Business Strategies and Development
9.5.16. Galapagos NV
9.5.16.1. Company Overview
9.5.16.2. Drug Class Portfolio
9.5.16.3. Financial Overview
9.5.16.4. Business Strategies and Development
9.5.17. Mitsubishi Tanabe Pharma
9.5.17.1. Company Overview
9.5.17.2. Drug Class Portfolio
9.5.17.3. Financial Overview
9.5.17.4. Business Strategies and Development
9.5.18. Boehringer Ingelheim Pharmaceuticals
9.5.18.1. Company Overview
9.5.18.2. Drug Class Portfolio
9.5.18.3. Financial Overview
9.5.18.4. Business Strategies and Development
9.5.19. Gilead Sciences Inc.
9.5.19.1. Company Overview
9.5.19.2. Drug Class Portfolio
9.5.19.3. Financial Overview
9.5.19.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations